Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Short-term EGFR blockade enhances immune-mediated cytotoxicity of EGFR mutant lung cancer cells: rationale for combination therapies.

Cell death & disease - 29 Sept 2016

Dominguez Charli, Tsang Kwong-Yok, Palena Claudia

Abstract excerpt

The epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) erlotinib has been approved for years as a first-line therapy for patients harboring EGFR-sensitizing mutations. With the promising implementation of immunotherapeutic strategies for the treatment of lung cancer, there is a growing interest in developing combinatorial therapies that could utilize immune approaches in the context of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Caspases

Share to Cytotoxicity, Immunologic

Share to Drug Resistance, Neoplasm

Share to Epithelial-Mesenchymal Transition

Share to Erlotinib Hydrochloride

Share to Interleukin-8

Source

Open in PubMed Open full text

Identifiers

PMID: 27685624
DOI: 10.1038/cddis.2016.297
PMCID: PMC5059888

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Short-term EGFR blockade enhances immune-mediated cytotoxicity of EGFR mutant lung cancer cells: rationale for combination therapies.PMID 27685624Read ↗

EGFR-Mutated Non-Small Cell Lung Cancer and Resistance to Immunotherapy: Role of the Tumor Microenvironment.Semantic proximity Read ↗

IL-8 signaling is involved in resistance of lung carcinoma cells to erlotinib.Semantic proximity Read ↗

Tumor regression mediated by oncogene withdrawal or erlotinib stimulates infiltration of inflammatory immune cells in EGFR mutant lung tumorsSemantic proximity Read ↗

CD8+ T-cell Responses Are Boosted by Dual PD-1/VEGFR2 Blockade after EGFR Inhibition in Egfr-Mutant Lung Cancer.Semantic proximity Read ↗

Tumor regression mediated by oncogene withdrawal or erlotinib stimulates infiltration of inflammatory immune cells in EGFR mutant lung tumors.Semantic proximity Read ↗

EGFR-mutant NSCLC may remodel TME from non-inflamed to inflamed through acquiring resistance to EGFR-TKI treatment.Semantic proximity Read ↗

Molecular and Clinical Features of EGFR-TKI-Associated Lung Injury.Semantic proximity Read ↗

Intratumor heterogeneity of EGFR expression mediates targeted therapy resistance and formation of drug tolerant microenvironment.Semantic proximity Read ↗

Perioperative immunotherapy for patients with EGFR mutant non-small cell lung cancer: Unexpected potential benefits.Semantic proximity Read ↗

Enhanced Efficacy of EGFR-Targeted ADCs via p38-Mediated Noncanonical Endocytosis in EGFR-Mutant Lung Cancer Cells.Semantic proximity Read ↗

MET-Induced CD73 Restrains STING-Mediated Immunogenicity of EGFR-Mutant Lung Cancer.Semantic proximity Read ↗

Immunogenic chemotherapy effectively inhibits KRAS-Driven lung cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.